Skip Navigation
AHRQ--Agency for Healthcare Research and Quality: Advancing Excellence in Health Care

Back to "About This Webcast"

Panel Biosketches


John Rumsfeld, M.D., Ph.D., FACC, FAHA, FACP, is a professor of medicine at the University of Colorado at Denver Health Sciences Center, a staff cardiologist at the Denver Veterans Affairs Medical Center, and a codirector of the Colorado Cardiovascular Outcomes Research (C-COR) Group. Among his many professional activities, Dr. Rumsfeld serves as the Acting National Director for Cardiology for the Veterans Health Administration, the National Director of the VA Cardiovascular Assessment, Reporting and Tracking (CART) Program, and the Clinical Coordinator of the VA Ischemic Heart Disease Quality Enhancement Research Initiative (IHD-QUERI). Dr. Rumsfeld also serves as the Chief Science Officer and Chair of the National Cardiovascular Data Registry (NCDR) for the American College of Cardiology (ACC) and is a member of the ACC Board of Trustees. He is the Vice-Chair of the Quality of Care and Outcomes Research (QCOR) Council for the American Heart Association, a member of the Cardiovascular Consortium Advisory Group for the DEcIDE (Developing Evidence to Inform Decisions about Effectiveness) Network sponsored by the Agency for Healthcare Research and Quality, and the Chair of the External Collaborations and Advisory Committee for the Cardiovascular Research Network (CVRN) sponsored by the National Heart, Lung, and Blood Institute.

Disclosure: Dr. Rumsfeld reports that he has nothing to disclose.


Lesley H. Curtis, Ph.D., is an associate professor of medicine in the Duke University School of Medicine and works primarily in the Center for Clinical and Genetic Economics. A health services researcher by training, Dr. Curtis oversees a portfolio of projects that use observational data to address questions related to clinical and comparative effectiveness, pharmacoepidemiology, health care delivery, and epidemiological trends.  She has published articles in JAMA, Medical Care, the Annals of Internal Medicine, JACC, and the Archives of Internal Medicine. Dr. Curtis has considerable experience analyzing Medicare claims data, large clinical registries, and prescription drug data, and has led the linkage of large clinical registries with longitudinal Medicare claims data. She is a coinvestigator for the AHRQ-sponsored Cardiovascular Center for Education and Research on Therapeutics (CERTS) and the Director of the Duke DEcIDE (Developing Evidence to Inform Decisions about Effectiveness) Center; she also leads the data core of the Sentinel Initiative for the U.S. Food and Drug Administration. Dr. Curtis is a coinvestigator in this study and coauthor of the paper.

Disclosure: Dr. Curtis reports that she has nothing to disclose.

Manesh Patel, M.D., is the Assistant Director and the Director of Research in the Cardiac Catheterization Laboratory at Duke University, Durham, North Carolina, and the Vice-Chair of the American Heart Association Committee on Diagnostic and Interventional Catheterization. Dr. Patel received his training in clinical research methods and outcomes research at the Duke Clinical Research Insititute in 2003–2005. He began work with the American College of Cardiology (ACC) Foundation Appropriateness Criteria Working Group in 2005 and was subsequently involved in authoring the Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaing that same year. He subsequently served in 2009 as the Chair of the writing group that reported Appropriateness Criteria for Coronary Revasculation in 2009 on behalf of the ACC Foundation Appropriateness Criteria for Coronary Revascularization Task Force and other professional societies. Dr. Patel has served as a member of other writing groups for other appropriate use criteria and in think tanks aimed at improving the quality of cardiovascular imaging. Dr. Patel’s clinical and research interests are in coronary and peripheral vascular disease and cardiovascular imaging, including cardiac magnetic resonance imaging and computerized tomography and vascular ultrasound. Dr. Patel is also involved in quality improvement projects in the Duke Catheterization Laboratory for both cardiac and peripheral vascular procedures. Dr. Patel is a coinvestigator in this study and coauthor of the paper.

Disclosure: Dr. Patel reports that he has nothing to disclose.

Kenneth Rosenfield, M.D., is the Head of the Section of Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital in Boston. His research interests are focused on the development of novel, minimally invasive strategies to treat complex peripheral and coronary artery disease. He has played a leading role in clinical trials to investigate the utility of renal, carotid, and lower extremity revascularization, intravascular ultrasound, excimer laser angioplasty, thrombolytic therapy, and other technologies in diagnosisng and treating cardiovascular disease. He also has worked with Dr. Jeffrey Isner to develop the concept of angiogenic therapy for critical limb ischemia. He is a longstanding member and a prior chairman of the Peripheral Vascular Disease Committee of the American College of Cardiology (ACC), the current Chair of the Diagnostic and Interventional Cardiac Catheterization Committee of the America Heart Association (AHA), and the current Chair of the Ad Hoc Committee on Peripheral Artery Disease and a member of the Ad Hoc Carotid and Cerebrovascular Disease Committee for the Society for Cardiovascular Angiography and Interventions (SCAI). Dr. Rosenfield has played a leadership role in defining new modalities of treatment and in expanding the role of the cardiologist and other specialists in the management of patients with peripheral vascular disease. He served on the organizing committee of the Vascular Centers Conference, where he worked to foster collaborations among specialists. This work has been brought to the local level, where he has played an instrumental role in creating a thriving, collaborative, integrated, multidisciplinary Vascular Program at his home institution, Massachusetts General Hospital. Finally, Dr. Rosenfield has played a prominent role in establishing guidelines and practice standards for the treatment of peripheral carotid, renal, and coronary artery disease. He served on the writing committees for the ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease, the ACC/AHA Clinical Competence Statement on the treatment of peripheral arterial disease (PAD), the TASC II Inter-Society Consensus for the Management of PAD, and the multidisciplinary Task Force that developed guidelines for training, competency, and credentialing for carotid intervention, which he also chaired. He regularly interfaces with members of the U.S. Food and Drug Administration and the Centers for Medicare and Medicaid Services, representing the cardiovascular community on various issues pertaining to PAD. He has run a fellowship program in vascular medicine at Massachusetts General Hospital for 19 years and has trained numerous physicians and other allied health care professionals in how to manage vascular and cardiovascular disease. He is also helping to develop novel modalities—namely, the use of medical simulators and specialized training programs—to educate physicians in the future. An example is the Foundation for Advanced Medical Education (FAME) Program, which he coordinated through the ACC, the SCAI, and the Society for Vascular Surgery. Dr. Rosenfield has numerous scientific publications to his credit and is a frequent contributor to book chapters and review articles on the management of PAD.

Disclosure: Non-public support of research: Abbott Vascular, Bard Peripheral Vascular, Cordis Endovascular, EV3/Medtronic; Intellectual property: Angioguard (Cordis); Advisory committee membership: Abbott Vascular, Boston Scientific, Lumen Biomedical, Inc., Micell Technologies; Consultancy: Abbott Vascular, Angioguard (Cordis), Boston Scientific, HCRI; Board membership: VIVA Physicians; Honorarium recipient: VIVA Physicians; Ownership Interests: Lumen Biomedical, Inc. Medical Simulation Corp., Micell Technologies.